Magnetic resonance fingerprinting in multiple sclerosis.
Magnetic resonance fingerprinting
Multiple sclerosis
Quantitative MRI
Relaxation
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
06
02
2023
revised:
15
08
2023
accepted:
23
09
2023
medline:
10
11
2023
pubmed:
3
10
2023
entrez:
2
10
2023
Statut:
ppublish
Résumé
In this cross sectional study, we used MRF to investigate tissue properties of normal-appearing white matter, gray matter, and lesions in relapsing remitting MS (n = 21), secondary progressive MS (n = 16) and healthy controls (n = 9). A FISP-based MRF sequence was used for acquisition, imaging time 5 min 15 s. MRF T1 and T2 relaxation times were measured from lesional tissue, normal-appearing frontal white matter, corpus callous, thalamus, and caudate. Differences between healthy controls and MS were examined using ANCOVA adjusted for age and sex. Spearman rank correlations were assessed between T1 and T2 relaxation times and clinical measures. To examine brain T1 and T2 values using magnetic resonance fingerprinting (MRF) in healthy controls and MS. The subjects included 21 relapsing-remitting (RR) MS, 16 secondary progressive (SP) MS, and 9 age- and sex-matched HC without manifest neurological disease participating in a longitudinal MRI study. A 3T/ FISP-based MRF sequence was acquired. Regions of interest were drawn for lesions and normal appearing white matter. ANCOVA adjusted for age and sex were used to compare the groups with significance set at 0.05. A step-wise increase in T1 and T2 relaxation times was found between healthy controls, relapsing remitting MS, and secondary progressive MS. Significant differences were found in T1 and T2 between MS and healthy controls in the frontal normal-appearing white matter, corpus callosum, and thalamus (p < 0.04 for all). Significant differences in T1 and T2 between RR and SPMS were found in the frontal normal-appearing white matter and T2 lesions (p < 0.02 for all). T1 relaxation from the frontal normal-appearing white matter correlated with the Expanded Disability Status Scale [ρ = 0.62, p < 0.001], timed 25 foot walk (ρ = 0.45, p = 0.01), 9 hole peg test (ρ = 0.62, p < 0.001), and paced auditory serial addition test (ρ = -0.4, p = 0.01). These results suggest that MRF may be a clinically feasible quantitative approach for characterizing tissue damage in MS.
Sections du résumé
BACKGROUND
BACKGROUND
In this cross sectional study, we used MRF to investigate tissue properties of normal-appearing white matter, gray matter, and lesions in relapsing remitting MS (n = 21), secondary progressive MS (n = 16) and healthy controls (n = 9). A FISP-based MRF sequence was used for acquisition, imaging time 5 min 15 s. MRF T1 and T2 relaxation times were measured from lesional tissue, normal-appearing frontal white matter, corpus callous, thalamus, and caudate. Differences between healthy controls and MS were examined using ANCOVA adjusted for age and sex. Spearman rank correlations were assessed between T1 and T2 relaxation times and clinical measures.
OBJECTIVES
OBJECTIVE
To examine brain T1 and T2 values using magnetic resonance fingerprinting (MRF) in healthy controls and MS.
METHODS
METHODS
The subjects included 21 relapsing-remitting (RR) MS, 16 secondary progressive (SP) MS, and 9 age- and sex-matched HC without manifest neurological disease participating in a longitudinal MRI study. A 3T/ FISP-based MRF sequence was acquired. Regions of interest were drawn for lesions and normal appearing white matter. ANCOVA adjusted for age and sex were used to compare the groups with significance set at 0.05.
RESULTS
RESULTS
A step-wise increase in T1 and T2 relaxation times was found between healthy controls, relapsing remitting MS, and secondary progressive MS. Significant differences were found in T1 and T2 between MS and healthy controls in the frontal normal-appearing white matter, corpus callosum, and thalamus (p < 0.04 for all). Significant differences in T1 and T2 between RR and SPMS were found in the frontal normal-appearing white matter and T2 lesions (p < 0.02 for all). T1 relaxation from the frontal normal-appearing white matter correlated with the Expanded Disability Status Scale [ρ = 0.62, p < 0.001], timed 25 foot walk (ρ = 0.45, p = 0.01), 9 hole peg test (ρ = 0.62, p < 0.001), and paced auditory serial addition test (ρ = -0.4, p = 0.01).
CONCLUSION
CONCLUSIONS
These results suggest that MRF may be a clinically feasible quantitative approach for characterizing tissue damage in MS.
Identifiants
pubmed: 37783196
pii: S2211-0348(23)00525-4
doi: 10.1016/j.msard.2023.105024
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105024Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest All authors have reviewed and approve the contents of the manuscript and all authors take full responsibility fotrthe analyses, interpretation, and conduct of the research, all had full access to all of the data and the right to publish all the data.. The manuscript is not under consideration for review elsewhere. All authors authorize the ISMRM to publish this financial disclosure with the article if deemed appropriate. DO: has received research support from National Multiple Sclerosis Society, National Institutes of Health, Patient Centered Outcomes Research Institute, Race to Erase MS Foundation, Genentech, Novartis, and Genzyme. He has also received consulting fees from Biogen Idec, Genentech/Roche, Genzyme, and Merck. VG: Grant support to CWRU by Siemens Healthineers. Patents on MR Fingerprinting, which have been licensed by Siemens Healthineers. AD: is a co-inventor on related patents which have been licensed by Siemens Healthcare. AS: Nothing to report. DG: Nothing to report. YJ: Nothing to Report. DM: Grant support to CWRU by Siemens Healthineers. Patents on MR Fingerprinting, which have been licensed by Siemens Healthineers. EF: Was an employee of and holds stock in Biogen at the time of publication, but not during data collection. RR: Was an employee of and holds stock in Biogen at the time of publication, but not during data collection. PR: Nothing to report. MK: Nothing to report. JAC:Personal compensation for consulting for Alkermes, Biogen, Convelo, EMD Serono, ERT, Gossamer Bio, Novartis, and ProValuate; speaking for Mylan and Synthon; and serving as an Editor of Multiple Sclerosis Journal. KS: Grant support from Genzyme and Novartis. ML: Research support from the National Multiple Sclerosis Society, the National Institutes of Health, the Department of Defense and consulting fees from Siemens Healthineers. MG: Grant support to CWRU by Siemens Healthineers. Patents on MR Fingerprinting, which have been licensed by Siemens Healthineers. KN: has received research support from National Multiple Sclerosis Society, National Institutes of Health, Patient Centered Outcomes Research Institute, Department of Defense, Biogen, Sanofi Genzyme, and Novartis; personal fee for consulting from NeuroRx, for speaking from Sanofi Genzyme, and for licensing fee from Biogen.